RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All MHRA (UK) updates
MHRA (UK)
OTHER
MHRA Safety Roundup: January 2026
Published: 1/27/2026Detected: 3/22/2026

Summary preview

Updates to safety guidance for medications and medical devices emphasize the need for timely reporting of adverse events and clarify the expectations for risk management plans.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
safety
#adverse events
#risk management
#patient safety
#labeling
#medical devices

Official Source Document
Source Verified

Access the original document directly from MHRA.

View Official Document

More from MHRA (UK)

  • Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
  • Field Safety Notices: 21 to 25 September 20269/29/2026
  • MHRA Safety Roundup: September 20269/29/2026
  • Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
  • Field Safety Notices: 14 to 18 September 20269/23/2026

Get MHRA (UK) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.